Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9

Table 2

ADME (adsorption, distribution, metabolism, and excretion) properties of compounds.

Number	ZINC ID	Solubility level^a	BBB level^b	CYP2D6 prediction^c	Hepatotoxicity^d	Absorption level^e	PPB prediction^f
1	ZINC000062238222	3	4	0	1	3	0
2	ZINC000085544839	3	4	0	1	3	0
3	ZINC000095620524	4	4	0	1	3	0
4	ZINC000004099069	3	4	0	0	3	0
5	ZINC000004654845	1	4	1	0	3	1
6	ZINC000085541163	2	4	0	0	2	0
7	ZINC000008552069	4	4	0	1	3	0
8	ZINC000013513540	4	4	0	1	3	0
9	ZINC000004228293	4	4	0	1	3	0
10	ZINC000009212428	4	4	0	1	3	0
11	ZINC000014952116	4	4	0	0	3	0
12	ZINC000014712793	4	4	0	0	3	0
13	ZINC000011616636	2	4	0	0	3	0
14	ZINC000008220036	0	4	1	0	3	1
15	ZINC000004096653	1	4	0	0	3	1
16	ZINC000012494317	1	4	1	0	3	0
17	ZINC000014951658	3	4	0	0	3	0
18	ZINC000085826835	2	4	0	0	2	0
19	ZINC000042805482	2	4	0	0	2	0
20	ZINC000004097774	2	4	0	0	3	0
21	6U3X	/	/	0	1	/	0

^aAqueous solubility level: 0 (extremely low); 1 (very low, but possible); 2 (low); and 3 (good); ^bblood-brain barrier level: 0 (very high penetrant); 1 (high); 2 (medium); 3 (low); and 4 (undefined); ^ccytochrome P450 2D6 level: 0 (noninhibitor) and 1 (inhibitor); ^dhepatotoxicity: 0 (nontoxic) and 1 (toxic); ^ehuman intestinal absorption level: 0 (good); 1 (moderate); 2 (poor); and 3 (very poor); ^fplasma protein binding: 0 (binding is <90%); 1 (binding is >90%); and 2 (binding is >95%).